IQVIA (IQV) Stock Forecast & Price Target

$220.64 +0.73 (+0.33%)

Closing price 10/24/2025 03:59 PM Eastern

Extended Trading

$219.80 -0.85 (-0.38%)

As of 10/24/2025 05:58 PM Eastern

Compare

IQVIA - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy

Based on 24 Analyst Ratings

Sell
0

Hold
5

Buy
19

Based on 24 Wall Street analysts who have issued ratings for IQVIA in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 5 have given a hold rating, 18 have given a buy rating, and 1 has given a strong buy rating for IQV.

Consensus Price Target

$234.57
6.31% Upside

According to the 24 analysts' twelve-month price targets for IQVIA, the average price target is $234.57. The highest price target for IQV is $270.00, while the lowest price target for IQV is $177.00. The average price target represents a forecasted upside of 6.31% from the current price of $220.64.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for IQV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IQVIA and its competitors.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IQV Analyst Ratings Over Time

Type	Current Forecast 10/25/24 to 10/25/25	1 Month Ago 9/25/24 to 9/25/25	3 Months Ago 7/27/24 to 7/27/25	1 Year Ago 10/26/23 to 10/25/24
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	18 Buy rating(s)	18 Buy rating(s)	17 Buy rating(s)	12 Buy rating(s)
Hold	5 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$234.57	$229.64	$228.62	$267.27
Forecasted Upside	6.31% Upside	29.95% Upside	14.78% Upside	24.52% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

IQV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IQV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

IQVIA Stock vs. The Competition

Type	IQVIA	Medical Companies	S&P 500
Consensus Rating Score	2.83	2.33	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	6.31% Upside	1,392.20% Upside	12.08% Upside
News Sentiment Rating	Positive News See Recent IQV News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/9/2025	HSBC 2 of 5 stars	Rajesh Kumar Not Rated	Upgrade	Hold ➝ Buy	$195.00 ➝ $235.00	+17.15%
10/9/2025	Hsbc Global Res 5 of 5 stars		Upgrade	Hold ➝ Strong-Buy
10/8/2025	Evercore ISI 3 of 5 stars	Elizabeth Anderson Not Rated	Boost Target	Outperform	$220.00 ➝ $240.00	+19.61%
10/8/2025	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold (C)
10/2/2025	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luke Sergott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$185.00 ➝ $200.00	-1.93%
9/9/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Windley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$195.00 ➝ $225.00	+19.86%
9/3/2025	Redburn Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jamie Clark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$214.00	+17.92%
7/25/2025	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ann Hynes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$190.00 ➝ $225.00	+13.90%
7/23/2025	Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
7/23/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Dan Leonard Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$185.00 ➝ $225.00	+15.70%
Get the Latest News and Ratings for IQV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter.
7/23/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
7/23/2025	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jailendra Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$209.00 ➝ $235.00	+22.12%
7/23/2025	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eric Coldwell Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$159.00 ➝ $196.00	+4.32%
5/22/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Neutral
5/19/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anne Samuel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$232.00 ➝ $177.00	+25.40%
2/11/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tejas Savant Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$245.00 ➝ $250.00	+24.05%
2/10/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	S. Dodge Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$270.00 ➝ $270.00	+31.00%
2/7/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shlomo Rosenbaum Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$273.00 ➝ $261.00	+24.95%
2/3/2025	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	D. Larsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
12/20/2024	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	J. Garro Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Overweight	$250.00	+30.53%
12/13/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$255.00 ➝ $235.00	+17.54%
11/19/2024	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$260.00 ➝ $248.00	+28.58%
11/1/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$270.00 ➝ $265.00	+27.09%
11/1/2024	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$270.00 ➝ $255.00	+22.30%
11/1/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$280.00 ➝ $250.00	+20.00%
10/14/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	J. Clark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$276.00	+20.32%
7/31/2024	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	S. Davis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform
2/15/2024	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 03:20 AM ET.

Should I Buy IQVIA Stock? IQV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, October 22, 2025. Please send any questions or comments about these IQVIA pros and cons to contact@marketbeat.com.

IQVIA
Bull Case

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

The company recently reported earnings per share (EPS) of $2.81, exceeding analyst expectations, which indicates strong financial performance and potential for growth.
IQVIA Holdings Inc. has shown a revenue increase of 5.3% compared to the same quarter last year, reflecting its ability to grow in a competitive market.
The current stock price is around $212, which is near its 52-week high, suggesting strong market confidence in the company's future prospects.
Analysts have a consensus rating of "Moderate Buy" for the stock, with a significant number of analysts issuing buy ratings, indicating positive sentiment among market experts.
The company boasts a return on equity of over 30%, which is a strong indicator of effective management and profitability, making it an attractive option for investors seeking solid returns.

IQVIA
Bear Case

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

Insider selling has been observed, with key executives reducing their holdings, which may signal a lack of confidence in the company's short-term performance.
The company's debt-to-equity ratio is relatively high at 2.45, indicating that it relies heavily on debt financing, which could pose risks in a rising interest rate environment.
Despite recent revenue growth, the net margin of 7.88% suggests that profitability may be under pressure, which could affect future earnings.
Market volatility could impact the stock price, as evidenced by fluctuations in the past year, making it a riskier investment in uncertain economic conditions.
While analysts have set optimistic price targets, any failure to meet these expectations could lead to a decline in stock value, affecting investor returns.

IQV Forecast - Frequently Asked Questions

: According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $234.57, with a high forecast of $270.00 and a low forecast of $177.00.
: 24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last twelve months. There are currently 5 hold ratings, 18 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IQV shares.
: According to analysts, IQVIA's stock has a predicted upside of 6.31% based on their 12-month stock forecasts.
: Over the previous 90 days, IQVIA's stock had 3 upgrades by analysts.
: IQVIA has been rated by research analysts at Barclays, Evercore ISI, Hsbc Global Res, HSBC, Jefferies Financial Group, Redburn Partners, and Weiss Ratings in the past 90 days.
: Analysts like IQVIA more than other "medical" companies. The consensus rating for IQVIA is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how IQV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:IQV) was last updated on 10/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IQVIA (IQV) Stock Forecast & Price Target